|
1
|
National Cancer Institute: Bladder Cancer
Treatment (PDQ®): Health Professional Version. National
Cancer Institute (US); Bethesda, MD: 2002, https://www.ncbi.nlm.nih.gov/books/NBK65962/
|
|
2
|
Packiam VT, Johnson SC and Steinberg GD:
Non-muscle-invasive bladder cancer: Intravesical treatments beyond
Bacille Calmette-Guérin. Cancer. 123:390–400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krishna SR and Konety BR: Current concepts
in the management of muscle invasive bladder cancer. Indian J Surg
Oncol. 8:74–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jeon HM and Lee J: MET: Roles in
epithelial-mesenchymal transition and cancer stemness. Ann Transl
Med. 5:52017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pradella D, Naro C, Sette C and Ghigna C:
EMT and stemness: Flexible processes tuned by alternative splicing
in development and cancer progression. Mol Cancer. 16:82017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lopez-Novoa JM and Nieto MA: Inflammation
and EMT: An alliance towards organ fibrosis and cancer progression.
EMBO Mol Med. 1:303–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tyagi A, Agarwal C, Dwyer-Nield LD, Singh
RP, Malkinson AM and Agarwal R: Silibinin modulates TNF-α and IFN-γ
mediated signaling to regulate COX2 and iNOS expression in
tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog.
51:832–842. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fabregat I, Fernando J, Mainez J and
Sancho P: TGF-beta signaling in cancer treatment. Curr Pharm Des.
20:2934–2947. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Helmy A, Hammam OA, El Lithy TR and El
Deen Wishahi MM: The role of TGF-beta-1 protein and TGF-beta-R-1
receptor in immune escape mechanism in bladder cancer. MedGenMed.
9:342007.PubMed/NCBI
|
|
10
|
Levy L and Hill CS: Alterations in
components of the TGF-beta superfamily signaling pathways in human
cancer. Cytokine Growth Factor Rev. 17:41–58. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bayram D, Çetin ES, Kara M, Özgöçmen M and
Candan IA: The apoptotic effects of silibinin on MDA-MB-231 and
MCF-7 human breast carcinoma cells. Hum Exp Toxicol. 36:573–586.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gu J, Tang SJ, Tan SY, Wu Q, Zhang X, Liu
CX, Gao XS, Yuan BD, Han LJ, Gao AP, et al: An open-label,
randomized and multi-center clinical trial to evaluate the efficacy
of Silibinin in preventing drug-induced liver injury. Int J Clin
Exp Med. 8:4320–4327. 2015.PubMed/NCBI
|
|
13
|
Li F, Ma Z, Guan Z, Chen Y, Wu K, Guo P,
Wang X, He D and Zeng J: Autophagy induction by silibinin
positively contributes to its anti-metastatic capacity via
AMPK/mTOR pathway in renal cell carcinoma. Int J Mol Sci.
16:8415–8429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma Z, Liu W, Zeng J, Zhou J, Guo P, Xie H,
Yang Z, Zheng L, Xu S, Wang X, et al: Silibinin induces apoptosis
through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell
carcinoma. Oncol Rep. 34:2461–2468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sozen H, Celik OI, Cetin ES, Yilmaz N,
Aksozek A, Topal Y, Cigerci IH and Beydilli H: Evaluation of the
protective effect of silibinin in rats with liver damage caused by
itraconazole. Cell Biochem Biophys. 71:1215–1223. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y,
Zhu G, Yang L, Wang X and He D: Silibinin reverses
epithelial-to-mesenchymal transition in metastatic prostate cancer
cells by targeting transcription factors. Oncol Rep. 23:1545–1552.
2010.PubMed/NCBI
|
|
17
|
Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang
Z, Wang Z, Zhang D, Xue Y, Chen Y, et al: Chemopreventive and
chemotherapeutic effects of intravesical silibinin against bladder
cancer by acting on mitochondria. Mol Cancer Ther. 10:104–116.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singh RP, Tyagi A, Sharma G, Mohan S and
Agarwal R: Oral silibinin inhibits in vivo human bladder tumor
xenograft growth involving down-regulation of survivin. Clin Cancer
Res. 14:300–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang
T, Zhang L, Chen Y, Gao Y, Wang B, et al: Silibinin inhibits
β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis
via dual-blocking epithelial-mesenchymal transition and stemness.
Cell Signal. 25:2625–2633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chandrasekaran S, Marshall JR, Messing JA,
Hsu JW and King MR: TRAIL-mediated apoptosis in breast cancer cells
cultured as 3D spheroids. Plos One. 9:e1114872014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brito RB, Malta CS, Souza DM, Matheus LH,
Matos YS, Silva CS, Ferreira JM, Nunes VS, França CM and Dellê H:
1-Methyl-D-tryptophan potentiates TGF-β-induced
epithelial-mesenchymal transition in T24 human bladder cancer
cells. PLoS One. 10:e01348582015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu CL, Ho JY, Chou SC and Yu DS: MiR-429
reverses epithelial-mesenchymal transition by restoring E-cadherin
expression in bladder cancer. Oncotarget. 7:26593–26603.
2016.PubMed/NCBI
|
|
24
|
Xian X, Huang L, Zhang B, Wu C, Cui J and
Wang Z: WIN 55,212-2 inhibits the epithelial mesenchymal transition
of gastric cancer cells via COX-2 signals. Cell Physiol Biochem.
39:2149–2157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kong D, Li Y, Wang Z and Sarkar FH: Cancer
stem cells and epithelial-to-mesenchymal transition
(EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel).
3:716–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vlahopoulos SA, Logotheti S, Mikas D,
Giarika A, Gorgoulis V and Zoumpourlis V: The role of ATF-2 in
oncogenesis. Bioessays. 30:314–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huber MA, Beug H and Wirth T:
Epithelial-mesenchymal transition: NF-kappaB takes center stage.
Cell Cycle. 3:1477–1480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katoh Y and Katoh M: Hedgehog signaling,
epithelial-to-mesenchymal transition and miRNA (Ρeview). Int J Mol
Med. 22:271–275. 2008.PubMed/NCBI
|
|
30
|
Ijaz T, Pazdrak K, Kalita M, Konig R,
Choudhary S, Tian B, Boldogh I and Brasier AR: Systems biology
approaches to understanding Epithelial Mesenchymal Transition (EMT)
in mucosal remodeling and signaling in asthma. World Allergy Organ
J. 7:132014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zarzynska JM: Two faces of TGF-beta1 in
breast cancer. Mediators Inflamm. 2014:1417472014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Iwano M: EMT and TGF-beta in renal
fibrosis. Front Biosci (Schol Ed). 2:229–238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Servais C and Erez N: From sentinel cells
to inflammatory culprits: Cancer-associated fibroblasts in
tumour-related inflammation. J Pathol. 229:198–207. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raposo TP, Beirão BC, Pang LY, Queiroga FL
and Argyle DJ: Inflammation and cancer: Till death tears them
apart. Vet J. 205:161–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu H, Ren G, Wang T, Chen Y, Gong C, Bai
Y, Wang B, Qi H, Shen J, Zhu L, et al: Aberrantly expressed Fra-1
by IL-6/STAT3 transactivation promotes colorectal cancer
aggressiveness through epithelial-mesenchymal transition.
Carcinogenesis. 36:459–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Jiao M, Wu K, Li L, Zhu G, Wang
X, He D and Wu D: TNF-α induced epithelial mesenchymal transition
increases stemness properties in renal cell carcinoma cells. Int J
Clin Exp Med. 7:4951–4958. 2014.PubMed/NCBI
|
|
37
|
Tong D, Liu Q, Liu G, Xu J, Lan W, Jiang
Y, Xiao H, Zhang D and Jiang J: Metformin inhibits
castration-induced EMT in prostate cancer by repressing
COX2/PGE2/STAT3 axis. Cancer Lett. 389:23–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tabriz HM, Olfati G, Ahmadi SA and
Yusefnia S: Cyclooxygenase-2 expression in urinary bladder
transitional cell carcinoma and its association with
clinicopathological characteristics. Asian Pac J Cancer Prev.
14:4539–4543. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deep G and Agarwal R: Antimetastatic
efficacy of silibinin: Molecular mechanisms and therapeutic
potential against cancer. Cancer Metastasis Rev. 29:447–463. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Imai-Sumida M, Chiyomaru T, Majid S, Saini
S, Nip H, Dahiya R, Tanaka Y and Yamamura S: Silibinin suppresses
bladder cancer through down-regulation of actin cytoskeleton and
PI3K/Akt signaling pathways. Oncotarget. 8:92032–92042. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gholami M, Moallem SA, Afshar M, Etemad L
and Karimi G: Gestational exposure to silymarin increases
susceptibility of BALB/c mice fetuses to apoptosis. Avicenna J Med
Biotechnol. 9:66–70. 2017.PubMed/NCBI
|
|
42
|
Tyagi AK, Agarwal C, Singh RP, Shroyer KR,
Glode LM and Agarwal R: Silibinin down-regulates survivin protein
and mRNA expression and causes caspases activation and apoptosis in
human bladder transitional-cell papilloma RT4 cells. Biochem
Biophys Res Commun. 312:1178–1184. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tyagi A, Agarwal C, Harrison G, Glode LM
and Agarwal R: Silibinin causes cell cycle arrest and apoptosis in
human bladder transitional cell carcinoma cells by regulating
CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Carcinogenesis. 25:1711–1720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yousefi M, Ghaffari SH, Zekri A, Hassani
S, Alimoghaddam K and Ghavamzadeh A: Silibinin induces apoptosis
and inhibits proliferation of estrogen receptor (ER)-negative
breast carcinoma cells through suppression of nuclear factor kappa
B activation. Arch Iran Med. 17:366–371. 2014.PubMed/NCBI
|
